Form 4: Allogene CEO Sells Shares for Tax Obligations

Allogene Therapeutics' President and CEO, David D. Chang, sold 47,763 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• David D. Chang, President and CEO of Allogene Therapeutics, Inc., reported a transaction on March 16, 2026.
• He sold 47,763 shares of Allogene Therapeutics common stock at a price of $2.47 per share.
• This sale was a 'sell to cover' transaction, mandated by the Issuer's equity incentive plan to satisfy tax withholding obligations from vested restricted stock units, and was not a discretionary trade.
• Following this transaction, Mr. Chang directly owns 5,150,599 shares of common stock.
• His indirect holdings include 856,044 shares via the RTC 2019 Trust, 856,044 shares via the JEC 2019 Trust, and 1,201,108 shares via the Chang 2006 Family Trust.
• The reported direct ownership also includes 12,500 shares acquired on March 15, 2026, through an employee stock purchase program.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and for tax purposes, which is a standard practice for executive equity compensation.

Positives

• The sale was non-discretionary, solely to cover tax withholding obligations, indicating it was not a reflection of management's view on the company's future prospects.
• The reporting person acquired 12,500 shares through an employee stock purchase program just prior to the reported sale, increasing his direct beneficial ownership.

Negatives

• A reduction of 47,763 shares in direct beneficial ownership occurred due to the 'sell to cover' transaction.

Future Outlook

NA

Management Comments

• "Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."
• "This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the reporting person."

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are common for executives receiving equity compensation and are generally not indicative of a change in sentiment regarding the company's prospects.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature of the sale for tax purposes suggests no change in management's confidence.

Key Dates

Recommendation

The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which does not signal a change in the company's fundamentals or management's outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Allogene Therapeutics, ALLO, insider trading, Form 4, stock sale, CEO, David D. Chang, restricted stock units, tax withholding, employee stock purchase program